

This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



June 24th, 2024

Company name: Modalis Therapeutics Corporation

Stock exchange listing: Tokyo Stock Exchange

Code number: 4883

URL: <https://www.modalistx.com/en/>

Representative: Haruhiko Morita

## **Modalis Therapeutics to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the 5<sup>th</sup> Annual Gene Therapy Immunogenicity Summit**

24-June-2024 TOKYO & Waltham, Mass – Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM<sup>®</sup> epigenome editing technology, announced that the company has been accepted for an Oral Presentation at the 5<sup>th</sup> Annual Gene Therapy Immunogenicity Summit (Aug 20-22, 2024, Boston, USA), and the following research results will be presented by our CSO, Dr. Tetsuya Yamagata.

- *Introducing the Cas9-mediated epigenome modulation platform for activating endogenous gene*
- *Immunogenicity of engineered capsid and transgene products and its impact on efficacy duration in disease model mice and NHPs*
- *Mechanism of tolerance and mitigation strategies for clinic.*

“Our proprietary and first-in-class CRISPR-based epigenome editing technology, CRISPR-GNDM<sup>®</sup>, regulates the expression levels of disease-causing genes or disease-modifier genes to treat genetic disorders,” said Dr. Tetsuya Yamagata, CSO of Modalis. “At this meeting, we will share data from our mouse and NHP studies that a counter-balanced immune response against Cas9-mediated epigenome modulation induces durable therapeutic efficacy. This data strongly demonstrates the safety of systemic administration of MDL-101 expressing the epigenome editor and suggests that MDL-101 will be an innovative therapy for LAMA2-CMD and that CRISPR-GNDM<sup>®</sup> is applicable to other systemic genetic disorders.” stated.

The Modalis Therapeutics presentation will be at the 5<sup>th</sup> Annual Gene Therapy Immunogenicity Summit (URL ; <http://genetherapy-immunogenicity.com>)

## **Oral Presentation:**

**Title:** Counter-balanced immune response against Cas9-mediated epigenetic modulation induces durable therapeutic efficacy

**Date and Time:** 8/22/2024, 12PM EST

**Session Name:** Talking Immunogenicity for Gene Edited Product

## **About the 5<sup>th</sup> Annual Gene Therapy Immunogenicity Summit**

Immunogenicity of AAV viral vectors and transgenes is one of the challenges in the development of safe and effective gene therapy. Experts in toxicology and immunology are scheduled to attend the focused conference to discuss the latest research findings regarding the prediction, measurement, and mitigation of immune responses from preclinical to clinical development. Through this conference, we will promote the industrial use of gene therapy by sharing learnings to gain a deeper understanding of the overall immune response to gene therapy and effective approaches to safely advance clinical development in line with regulatory expectations.

## **About MDL-101**

MDL-101 is an experimental, epigenome modulation therapy under investigation for the treatment of LAMA2-Congenital Muscular Dystrophy (LAMA2-CMD). MDL-101 is comprised of guide nucleotide targeting LAMA-1 gene, a highly homologous sister gene of the disease-causing gene LAMA-2, enzyme-null Cas9 (dCas9) fused with trans-activating domain driven by a muscle-specific promoter and coded in a muscle-specific AAV vector. MDL-101 upregulates LAMA-1 gene products in patients' muscle tissue to compensate for loss-of-function caused by mutation of LAMA-2, and therefore has the potential to provide a one-time, durable treatment benefit for people living with LAMA2-CMD.

## **About Modalis:**

Modalis Therapeutics develops precision genetic medicines using epigenome editing technology. Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM<sup>®</sup> technology which enables the gene/locus-specific modulation of gene expression or epigenetic editing without the need for DNA cleavage or altering DNA sequence. Headquartered in Tokyo with laboratories and facilities in Waltham Massachusetts, the company is listed on Tokyo Stock Exchange's Growth market. For additional information, visit [www.modalistx.com](http://www.modalistx.com).